What's happening in Technology Transfer at Wellcome

1
What's happening in Technology Transfer at
Wellcome
Ted Bianco
2
Purpose To maximise the impact of research
innovations on health by facilitating their
route to the market

• focused on funding gaps
• motivated by public good
• committed to adding value

3
TechTransfer team
4
Translation funding to date
Input

• 180 projects supported
• Range 25K - 11.2M
• 229 million committed

5
Translation funding to date
Input

• 180 projects supported
• Range 25K - 11.2M
• 229 million committed
• 419 million leveraged
• 10 exits via MA/listing
• or licensing
• 6 products launched

Output
6
Diversity of Translation Award scheme
Applications received

Awards made
7
(No Transcript)
8
Seeding Drug Discovery
Vital statistics Total fund 91 million Period
2006-2011 Awards 25 projects (6 rounds) Spend
68 million committed Award rate by number 9
(54 after shortlisting) Award rate by value 14
(44 after shortlisting) Average award 3.0
million

Progress to date through project milestones (MS)
9
Seeding Drug Discovery
The emerging portfolio
10
Strategic funding overseas is growing in parallel
Response mode funding in UK is well
established(34 institutions, 31 companies)
11
Technology Transfer global activities

• Typhoid multivalent vaccine (Italy)
• H5N1 antibodies (USA, Switzerland)
• STD diagnostics (UK, USA)
• Emergency fever therapy (Thailand, UK)
• NITD (Singapore, USA, Holland)
• Dengue drug discovery (Belgium)

• Oral pandemic flu vaccine (USA)
• Antibiotic drug discovery x 2 (USA)
• Sandfly trap (UK, Brazil)
• TB diagnostics (UK, Malawi)
• TB vaccine (UK, USA, S Africa)
• Typhoid oral vaccine (USA Vietnam)

12
Technology Transfer global activities

• Typhoid multivalent vaccine (Italy)
• H5N1 antibodies (USA, Switzerland)
• STD diagnostics (UK, USA)
• Emergency fever therapy (Thailand, UK)
• NITD (Singapore, USA, Holland)
• Dengue drug discovery (Belgium)

• Oral pandemic flu vaccine (USA)
• Antibiotic drug discovery x 2 (USA)
• Sandfly trap (UK, Brazil)
• TB diagnostics (UK, Malawi)
• TB vaccine (UK, USA, S Africa)
• Typhoid oral vaccine (USA Vietnam)

Indian Affordable Healthcare
13
Health inequity is shocking ........but well
recognised
Where the World's infants die
Where the World's centurians die
14
Living with ill-health is more 'equitably' spread
.but it shackles human development
15
Living with ill-health is more 'equitably' spread
.but it shackles human development
Malaria 20 million cases Tuberculosis 4.5
million cases HIV infections 3 million cases
16
Living with ill-health is more 'equitably' spread
.but it shackles human development
Malaria 20 million cases Tuberculosis 4.5
million cases HIV infections 3 million cases
Road accidents 1.3 million injuries
Cardiovascular 3 million events Diabetes 32
million cases
17
The Indian paradox
GDP in 2005 exceeded most EU nations
40 live on lt1/day 80 live on lt2/day
18
Indian industry a healthcare opportunity for the
poor

• Founded in the 1960s
• Grown as family businesses
• Based on generics
• Aimed at the mass market

• Historic growth not RD based
• Home-grown innovation is new
• Low cost products are a niche
• Globalising fast

19
Key strengths
Western-style production at low cost
Superior capacity for clinical trials
Large domestic market and rapid export growth
20
Indian Affordable Healthcare
New, 30M scheme, launched October 2008 Local
sourcing of projects Funding by dedicated India
committee

• Focus on
• the poor
• the marginalised (eg rural communities)
• the poverty trap escape generation
• Looking for
• Affordability
• Dissemination potential
• Health impact

21
Medical Engineering
Joint initiative with the Engineering and
Physical Sciences Research Council. 41 M for
four centres of excellence Leeds University
(John Fisher) Focus on ageing in relation to
early diagnosis improved prostheses for
musculo-skeletal cardiovascular
disease. Oxford University (Lionel Tarassenko)
Focus on personalised treatment in chronic
conditions such as asthma, diabetes cancer
using telemedicine technology. Imperial College
(Ross Ethier) Focus on the management of
osteoarthritis through improved implants and
tissue engineering approaches. Kings College,
London (Reza Razavi) Focus on medical imaging in
cardiovascular disease and cancer for improved
visualisation to guide targeted therapy
22
1919
The march of progress
23
1919
2009
The march of progress
24
1919
2009
The march of progress
25
1919
2009
The march of progress
26
1919
2009
The march of progress
27
Tuberculosis Death toll 50,000 a week (2
billion infections)

• Vaccine trial
• Collaboration between University of Oxford,
  Emergent Biosolutions and Aeras
• Based on 'Prime-Boost' strategy
• BCG provides prime
• MVA85A provides boost
• Phases 1 and 2a completed
• Phase 2b initiated in June 2009
• 2800 children at Worcester, South Africa
• First TB vaccine efficacy trial in 80 years

28
A final word from the walking wounded.....
Leishmaniasis Malaria
Tuberculosis
Detached retina Breast cancer
Equine strangles
" It's in your DNA to innovate, so put some skin
in the game! "